In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Krsnaa Diagnostics has commenced its fourth out of eight Diagnostics Center in Ayodhya
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Gafchromic films support patient care in oncology
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
The blood test market worldwide is today around $75-80 billion
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
Alpenglow has created an end-to-end 3D spatial biology solution including patented high-throughput 3D imaging
Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
This new capability represents a significant shift from a microscope-based standard of care to the use of digital whole slide images
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Diagnostic imaging will become an increasingly vital process in healthcare
Subscribe To Our Newsletter & Stay Updated
